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Abstract
One of the main goals of sequential, multiple assignment, randomized trials (SMART) is to find the
most efficacious design embedded dynamic treatment regimes. The analysis method known as multiple
comparisons with the best (MCB) allows comparison between dynamic treatment regimes and identifi-
cation of a set of optimal regimes in the frequentist setting for continuous outcomes, thereby, directly
addressing the main goal of a SMART. In this paper, we develop a Bayesian generalization to MCB
for SMARTs with binary outcomes. Furthermore, we show how to choose the sample size so that the
inferior embedded DTRs are screened out with a specified power. We compare log-odds between different
DTRs using their exact distribution without relying on asymptotic normality in either the analysis or
the power calculation. We conduct extensive simulation studies under two SMART designs and illustrate
our method’s application to the Adaptive Treatment for Alcohol and Cocaine Dependence (ENGAGE)
trial.
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1 Introduction
Substance use disorders are a common yet debilitating group of conditions for which treatment response is
highly variable (McKay, 2009; Kranzler & McKay, 2012; Black & Chung, 2014; Witkiewitz et al. , 2015).
While there exist interventions, physicians often must rely on clinical experience to choose subsequent ther-
apies for individuals who have failed to respond to initial treatment. In order to personalize medicine, there
is a need for longitudinal trial data as well as methodologies for comparing sequences of treatment decision
rules.
Sequential, multiple assignment, randomized trial (SMART) designs are a type of longitudinal clinical
trial specifically designed to determine the optimal sequence of decision rules called dynamic treatment
regimes (DTRs) (Lavori et al. , 2000; Murphy, 2005; Lei et al. , 2012; Rose et al. , 2019; Murphy et al. ,
2001; Murphy, 2003; Robins, 2004; Nahum-Shani et al. , 2012; Chakraborty & Moodie, 2013; Chakraborty
& Murphy, 2014; Laber et al. , 2014). In particular, there are DTRs embedded in the SMART by design;
hence, SMARTs provide evidence for the regime tailored to a subject’s response.
Standard multiple comparison approaches used to control for type I errors result in a loss of statistical
power. This is critically important when working with smaller data sets such as clinical trials. Ertefaie et al.
(2015) introduced a frequentist semiparametric model for estimation of the embedded DTR outcomes as
well as continuous outcome multiple comparisons with the best (MCB) for comparing the embedded DTRs.
MCB enables the construction of a set of optimal embedded DTRs which are statistically indistinguishable
for the available data. MCB offers increased power while controlling the type I error rate so that the best
embedded DTR is included with a specified probability (Hsu, 1981, 1984, 1996; Artman et al. , 2018). By
requiring only L−1 comparisons where L is the number of embedded DTRs compared with all
(
L
2
)
pairwise
comparisons, MCB yields greater power over other methods. However, applications of MCB have focused
on continuous outcomes.
Binary outcomes arise frequently as primary outcomes in psychiatry and addiction clinical trials. The
exiting methods for estimation in SMARTs with binary outcomes do not permit complex comparisons be-
tween all of the embedded DTRs such as with MCB (Kidwell et al. , 2018; Dziak et al. , 2019). Moreover,
the power analysis approaches for a SMART almost entirely focus on continuous outcomes aiming to size
a SMART for simple comparisons between two embedded DTRs or to power a SMART so that the best
embedded DTR has the largest point estimate with a specified probability (Crivello et al. , 2007a,b). More
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recently, Rose et al. (2019) proposed a method which relies on Q-learning for continuous outcomes to size
a SMART. Kidwell et al. (2018) developed a sample size calculator for binary outcome SMARTs, but their
method is restricted to comparisons between only two embedded DTRs. Furthermore, they assume asymp-
totic normality which may not hold due to the small sample size of embedded treatment sequences in a
SMART.
Yan et al. (2020) developed a frequentist sample size calculation method for pilot SMARTs. In particular,
they size a SMART so that the mean outcome of a DTR is within “a margin of error”. In other words, so that
confidence intervals are less than a pre-specified length. Advantages of their method include applicability to
continuous, count, and binary outcomes. A limitation is that normality is assumed for all outcome summary
statistics including log-OR. However, this may be unreasonable due to the small sample size in each branch
of the SMART. This could be problematic especially in a pilot SMART for which the sample size is small
by design. An advantage of our method is it does not make such strong parametric assumptions and uses
uninformative priors to avoid bias. An important similarity of their method to ours is taking into account
uncertainty in sample size calculations rather than only viewing the problem as that of estimation. In
addition, for our method, the best embedded DTR will be included with a given probability. In summary,
our method makes comparisons between > 2 embedded DTRs adjusting for multiplicity, rather than looking
at them marginally. The authors of Yan et al. (2020) emphasize if there is no hypothesis testing in the pilot
SMART, then standard power analysis is not relevant. Therefore, their method fills an important gap for
pilot SMARTs. However, in this article, we are interested in drawing inference on the optimal embedded
DTRs and sizing SMARTs for this purpose.
Ogbagaber et al. (2016) presented a method for power analysis based off an omnibus test as well as
all pairwise comparisons for continuous outcomes. Artman et al. (2018) proposed a power analyses for
SMARTs using MCB approach. Specifically, the latter method computes the number of individuals to enroll
in a SMART in order to achieve a specified power to exclude embedded DTRs inferior to the best by a given
amount from the set of best. This approach, however, relies on the normality assumption of the outcome,
and thus, cannot always be used with binary outcomes.
In this article, we extend MCB to the Bayesian binary outcome setting to directly address current
methods’ limitations. We build upon the work in Artman et al. (2018) to develop a rigorous power analysis
procedure. We simulate from the posterior of each parameter for each treatment sequence individually
which are independent. This circumvents the need for specifying the correlation matrix of the random
embedded DTR outcomes in the frequentist setting. Then, using Robin’s G-computation formula for a
dynamic regime (Robins, 1986), we represent each embedded DTR outcome as a weighted average of the
independent treatment sequences. We use the transformed draws in the MCB procedure to facilitate Bayesian
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inference. We leverage the method in Mandel & Betensky (2008) to extend the MCB methodology to use
Monte Carlo draws in the construction of the set of best embedded DTRs. In particular, it enables the
construction of simultaneous one-sided upper credible intervals for log-odds ratios, comparing each embedded
DTR to the best embedded DTR when the outcome is binary. Our proposed approach obviates many of the
challenges associated with the current methods of choice, namely
(i) in contrast with the method of Artman et al. (2018), our Bayesian MCB method can be used directly
with binary outcomes and our power analysis requires fewer parameter specification;
(ii) in contrast with the existing multiple comparison approaches, our approach performs fewer compar-
isons which increases the statistical power; and
(iii) is designed specifically for statistical inference for complex comparisons of > 2 embedded DTRs and
is applicable to small sample size.
In Section 2, we introduce the ENGAGE SMART. In Section 3, we formalize notation and present our
Bayesian binary outcome model. In Section 4, we provide details about about Bayesian MCB. We then show
how to perform power analysis. In Section 5, simulation studies are conducted. In Section 6, we illustrate
our method on the the real ENGAGE SMART. In Section 7, we outline how to choose the input parameters
for sample size determination. In Section 8, we conclude with discussion. The Appendix provides proofs.
2 The ENGAGE trial
In the Adaptive Treatment for Alcohol and Cocaine Dependence SMART (ENGAGE; Figure 1), individuals
were initially randomized to two different treatments: motivational interviewing (MI) for intensive outpatient
programs (IOP) and for patient’s choice (PC). PC consisted of an intervention which the patient chooses.
Patients who were non-engagers (did not attend any therapy sessions) at 2 weeks were enrolled. After 8 weeks,
those who failed to attend any sessions during weeks 7 and 8 were classified as non-responders/non-engagers
and were re randomized to either MI-PC or No Further Care (NFC). Those who were still responders were
assigned to NFC. The original study analysis suggested that MI-IOP was significantly more effective than
MI-PC. In this paper, we analyze the SMART to compare embedded DTRs. We restrict our attention in the
study to individuals who did not engage by week 2 which yielded a sample size 148. One of the main goals
of SMART designs is the identification of the best embedded DTRs for a primary outcome (Nahum-Shani
et al. , 2012). We construct a binary outcome which is whether the log of the total number of drinking days
plus cocaine use days was less than the 25th percentile of the log of the total number of drinking days plus
cocaine use days.
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Figure 1: Structure of the ENGAGE trial.
Determination of optimal embedded DTRs would provide evidence-based recommendations for clinicians
when treating individual patients with substance use disorders. The ENGAGE study aimed to determine
the optimal treatment for non-responders (McKay et al. , 2015; Van Horn et al. , 2015). There were four
embedded DTRs. Two of the embedded DTRs were as follows:
1. Start with MI+IOP. If the subject is engaged during the first 8 weeks, then at the 8-week point, offer
NFC; if the subject is labeled as a non-engager at week 8 of follow-up, offer MI+PC.
2. Start with MI+IOP. If the subject is engaged during the first 8 weeks, then at the 8-week point, offer
NFC; if the subject is labeled as a non-engager at week 8 of follow-up, offer NFC.
The other two embedded DTRs are similar (see Table 1). See McKay et al. (2015); Van Horn et al. (2015)
for more details about the SMART.
3 Framework
3.1 Notation
We focus on a SMART in which there are two stages where at each stage, individuals are randomized to
different treatment options. By design, stage-2 treatment is commonly tailored based on a patient’s ongoing
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Figure 2: Diagram of the General SMART.
response status which generates the different embedded DTRs (see Figures 1 and 2). Let Y (l) denote the
binary potential outcome for an individual following embedded DTR l ∈ {1, ..., L}. Let Yk denote the binary
potential outcome for an individual following treatment sequence k ∈ {1, ...,K}. Let A1 ∈ {−1,+1} denote
the stage-1 treatment assignment indicator. Let AR2 ∈ {−1,+1} denote the stage-2 treatment assignment
indicator for responders and ANR2 ∈ {−1,+1} be the treatment assignment indicator for non-responders. Let
Si denote the observed stage-1 treatment response indicator. Let θ
(l) be the probability of response in the
lth embedded DTR, l = 1, ..., L, where we assume that the Lth embedded DTR is the best. Let θk denote the
probability of response in the kth treatment sequence, k = 1, ...,K. Let Zi ∈ {1, ...,K} denote the treatment
sequence indicator for subject i.
Then, the log-odds ratio for the lth embedded DTR compared with the best embedded DTR is ζ(l) =
log
(
Odds(l)
Odds(L)
)
= log(Odds(l)) − log(Odds(L)) and Odds(l) = θ
(l)
1− θ(l) . We do not make any distributional
assumptions about the log-odds or the log-odds ratio. Assuming that being equal to 1 is the desirable out-
come, higher log-odds (and equivalently, log-odds ratios) implies superiority of the corresponding embedded
DTR.
3.2 Binary outcome models
We assume observations Y obsi
iid∼ Bern(θZi) where Zi is the treatment sequence followed by the ith individual
and Si
iid∼ Bern(λA1) for i = 1, ..., n where A1 is the stage-1 treatment. Our target parameter is the probability
of response at the end of the trial (Y (l) = 1) for a particular embedded DTR. Using Robins’ G-computation
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Embedded Dynamic Treatment Regime
1 A1 = +1, S = 1 or A1 = +1, S = 0, A2 = +1
Receive MI-IOP, if respond receive NFC, if not respond switch to MI-PC
2 A1 = +1, S = 1 or A1 = +1, S = 0, A2 = −1
Receive MI-IOP, if respond, receive NFC, if not respond, receive NFC
3 A1 = −1, S = 1 or A1 = −1, S = 0, A2 = +1
Receive MI-PC, if respond receive NFC, if not respond switch to MI-PC
4 A1 = −1, S = 1 or A1 = −1, S = 0, A2 = −1
Receive MI-PC, if respond receive NFC, if not respond, receive NFC.
Table 1: Embedded dynamic treatment regime decision rules for the ENGAGE trial. MI-IOP: motivational
interviewing for intensive outpatient program. MI-PC: motivational interviewing for patient choice. NFC:
no further care.
formula (Robins, 1986), we have the following representation for the target parameter:
Pr(Y (l) = 1) = Pr(Y = 1 |A1 = a1l, S = 1, AR2 = a2l) Pr(S = 1 | A1 = a1l)+ (1)
Pr(Y = 1 | A1 = a1l, S = 0, ANR2 = a2l) Pr(S = 0 | A1 = a1l), l = 1, 2, · · · , L.
Thus, the mean outcome under each embedded DTR is a weighted average of the responder treatment
sequence outcome and the non-responder treatment sequence outcome. This permits estimation and inference
without using a marginal structural model. While baseline covariates could be included in (1), for the purpose
of power analysis, we define the target parameter as a marginalized quantity. In our Bayesian procedure, we
impose a non-informative prior on θk and λA1 which results in beta posterior distributions. We then define
the treatment sequence response probabilities θR = Pr(Y = 1 | A1 = a1l, S = 1, AR2 = a2l), θNR = Pr(Y = 1 |
A1 = a1l, S = 0, A
NR
2 = a2l). Lastly, the probability of response in stage 1 for those assigned to A1 is given
by λA1 = Pr(S = 1 | A1 = a1). We leverage (1) to transform each MCMC draw to the target parameter and,
subsequently, into a log-odds ratio. By taking this simulation based approach, we avoid making normality
assumptions. At the mth iteration of the MCMC, we draw θR,m, θNR,m, and λA1,m. Hence, the m
th draw
of the probability of response for the lth embedded DTR is θ
(l)
m = θR,mλA1,m + θNR,m(1− λA1,m).
The mth draw of the log-odds ratio is ζ
(l)
m = log OR
(l) = log
(
θ(l)m
1−θ(l)m
)
− log
(
θ(L)m
1−θ(L)m
)
. Next, we specify
the likelihoods. The likelihood for the observed end-of-study outcomes is given by the following f(Y1, ..., Yn |
θ1, ..., θk) ∝
∏n
i=1 θ
Yi
Zi
(1 − θZi)1−Yi , where the treatment sequence indicator is Zi ∈ {1, ...,K}. We then
assume a non-informative uniform prior on θk, k ∈ {1, ...,K} which yields the posterior of θk given by the
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Embedded Dynamic Treatment Regime
1 A1 = +1, S = 1, A
R
2 = +1 or A1 = +1, S = 0, A
NR
2 = +1
Receive Trt. 1, if respond, continue Trt 1, if not respond, switch to Trt 4.
2 A1 = +1, S = 1, A
R
2 = +1 or A1 = +1, S = 0, A
NR
2 = −1
Receive Trt. 1, if respond continue Trt 1, if not respond, add Trt. 4
3 A1 = +1, S = 1, A
R
2 = −1 or A1 = +1, S = 0, ANR2 = +1
Receive Trt 1, if respond add Trt 3, if not respond switch to Trt 4
4 A1 = +1, S = 1, A
R
2 = −1 or A1 = +1, S = 0, ANR2 = −1
Receive Trt. 1, if respond add Trt 3., if not respond add Trt. 4.
5 A1 = −1, S = 1, AR2 = +1 or A1 = −1, S = 0, ANR2 = +1
Receive Trt. 2, if respond continue Trt. 2., if no respond switch to Trt 4.
6 A1 = −1, S = 1, AR2 = +1 or A1 = −1, S = 0, ANR2 = −1
Receive Trt. 2, if respond, continue Trt. 2, if not respond, add Trt 4.
7 A1 = −1, S = 1, AR2 = −1 or A1 = −1, S = 0, ANR2 = +1
Receive Trt.2, if respond add Trt. 3, if not respond switch to Trt 4.
8 A1 = −1, S = 1, AR2 = −1 or A1 = −1, S = 0, ANR2 = −1
Receive Trt. 2, if respond add Trt. 3., if not respond, add Trt 4.
Table 2: Embedded dynamic treatment regime decision rules for the General SMART.
following:
f(θk | y1, ..., yn) ∼ Beta
( ∑
i:Zi=k
Yi + 1,
∑
i:Zi=k
1−
∑
i:Zi=k
Yi + 1
)
Furthermore, the posterior of the stage-1 response probabilities are given by
f(λA1 | S1, ..., Sn) = Beta
( ∑
i:A1i=A1
Si + 1,
∑
i:A1i=A1
1−
∑
i:A1i=A1
Si + 1
)
4 MCB for binary outcomes
4.1 Simultaneous credible intervals for Monte Carlo draws
In this section, we describe our MCB procedure based off Mandel & Betensky (2008) to construct simultane-
ous 100(1− α)% one-sided upper credible intervals using multivariate draws from an arbitrary distribution.
Their method was originally designed to construct confidence intervals for draws obtained using the boot-
strap. In Section A.1. of the Appendix, we show that the latter approach is also applicable to Monte Carlo
simulation draws of the posterior. The following theorem forms the basis for the extension of MCB to the
Bayesian setting.
Theorem 1. Let ζ
(l)
m , l = 1, · · · , L, m = 1, · · · ,M denote draws of the parameters ζ(l) obtained from
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Monte Carlo simulation. Let r(m, l) denote the rank of ζ
(l)
m and assume no ties. Then, U (l) = ζ
(l)
(r1−αl)
, l =
1, · · · , L− 1 are simultaneous 1− α level upper credible intervals for ζ(l), l = 1 · · · , L− 1 where r1−α is the
(1− α)th quantile of maxl r(m, l) for each draw m = 1, · · · ,M .
The goal is to construct upper credible interval limits U (l), l = 1, · · · , L which jointly have coverage
1−α. Note that there is a one-to-one correspondence between a draw ζ(l)m and its rank r(m, l) in the absence
of ties where m is the mth draw, m = 1, · · · ,M . In particular, ζ(l)(r(m,l)) = ζ(l)m . Then, ζ(l)m is less than
U (l) for all l = 1, · · · , L for 100(1 − α)% of the draws m = 1, · · · ,M if and only if ζ(l)(r(m,l)) is less than
U (l) for all l = 1, · · · , L for 100(1 − α)% of the draws m = 1, · · · ,M . A sufficient condition is for r(m, l)
to be less than some integer r1−α for all l, for 100(1 − α)% of the r(m, l), l = 1, · · · , L, m = 1, · · · ,M .
Equivalently, the max rank across embedded DTRs r(m) := maxl r(m, l) is less than r1−α for 100(1−α)% of
the draws m = 1, · · · ,M . Let r1−α equal the 1− α quantile of r(1), · · · , r(M). Then, letting U (l) = ζ(l)(r1−αl)
for l = 1, · · · , L completes the proof. See the Appendix for more details. The proof that the algorithm
works assumes no ties. When there are ties in rank, one can use the minimum rank to obtain coverage near
100(1− α)% for a sufficiently large number of draws (Mandel & Betensky, 2008).
Define Bˆ = {EDTR(l) | U (l) ≥ 0} where U (l) is the upper credible limit for the difference between the
lth embedded DTR’s log-odds and the best embedded DTR’s log-odds. Then, regardless of sample size, Bˆ
contains the true optimal embedded DTR with probability at least 1 − α by construction. It furthermore
adjusts for multiplicity by the above procedure. We define Bˆ to be the set of best embedded DTRs as it
contains embedded DTRs which are not statistically significantly inferior to the best embedded DTR. This
is analogous to MCB constructed for continuous outcomes in Ertefaie et al. (2015). Sample sizes which are
larger shrink Bˆ so that inferior embedded DTRs are excluded. In the next section, we prove how to choose
the sample size to achieve this goal.
4.2 Power calculation with binary outcomes
In the last section, we demonstrated how to construct a set of optimal embedded DTRs. In this section,
we show how to size a SMART to obtain a set of embedded DTRs which are not different in their efficacy
by a clinically meaningful amount. In terms of the credible intervals, those which cover 0 correspond with
embedded DTRs which are not statistically distinguishable from the optimal embedded DTR. Those that
are strictly below 0 are inferior and are subsequently excluded from the set of best. We present how to
perform power analysis for Bayesian MCB with a binary outcomes.
Let η be the known inputs (response probabilities at each stage). We wish to determine the sample size
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n such that
Pr
 ⋂
l:∆l≥∆
{
U (l) < 0
}
| η
 = 1− γ
where 1 − γ is the power, ∆ is the clinically meaningful difference with the best embedded DTR and ∆l is
the log-odds ratio between the lth embedded DTR and the best embedded DTR, Without loss of generality,
assume that Y new is a sufficient statistic for η. Then,
Pr
 ⋂
l:∆l≥∆
{
U (l) < 0
}
| η
 = ∫ Pr
 ⋂
l:∆l≥∆
{
U (l) < 0
}
| Y new,η
 p(Y new | η)dY new
=
∫ ∫
Pr
 ⋂
l:∆l≥∆
{
U (l) < 0
}
| Y new,η, φ(1), ..., φ(M)
 p(φ(1), ..., φ(M) | Y new)p(Y new | η)dφdY new,
where φ(1), ..., φ(M) are independent of η given Y new by sufficiency and are draws of the parameters for which
we are constructing upper credible intervals. Therefore,
∫ ∫
Pr
 ⋂
l:∆l≥∆
{
U (l) < 0
}
| Y new,η, φ(1), ..., φ(M)
 p(φ(1), ..., φ(M) | Y new)p(Y new | η)dφdY new
=
∫ ∫
Pr
 ⋂
l:∆l≥∆
{
U (l) < 0
}
| φ(1), ..., φ(M)
 p(φ(1), ..., φ(M) | Y new)p(Y new | η)dφdY new
=
∫ ∫
I
 ⋂
l:∆l≥∆
{
U (l)(φ(1), ..., φ(M)) < 0
} p(φ(1), ..., φ(M) | Y new)p(Y new | η)dφdY new
≈ 1
I1
I1∑
i=1
∫
I
 ⋂
l:∆l≥∆
{
U (l)(φ(1),i, ..., φ(M),i) < 0
} p(φ(1),i, ..., φ(M),i | Y new,i)dφ,
where U (l)(·, ..., ·) maps the posterior draws to the kth simultaneous credible interval as determined by the
procedure in the previous section. Furthermore, Y new,i ∼ p(Y new | η) for all i = 1, ..., I1. In the above, we
have used the Law of Large Numbers. Similarly,
1
I1
I1∑
i=1
∫
I
 ⋂
l:∆l≥∆
{
U (l)(φ(1),i, ..., φ(M),i < 0
} p(φ(1),i, ..., φ(M),i | Y new,i)dφ
≈ 1
I1
I1∑
i=1
1
J1
J∑
j=1
I
 ⋂
l:∆l≥∆
{
U (l)(φ
(1),i
j , ..., φ
(M),i
j ) < 0
} ,
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where φ
(m),i
j ∼ p(φ | Y new,i) and Y new,i ∼ p(Y new | η). In summary,
Pr
 ⋂
l:∆l≥∆
{
U (l) < 0
}
| η
 ≈ 1
I1
I1∑
i=1
1
J1
J∑
j=1
I
 ⋂
l:∆l≥∆
{
U (l)
(
φ
(1),i
j , ..., φ
(M),i
j
)
< 0
} .
Therefore, we may choose a sample size that yields 100(1− γ)% power by the following procedure.
Specify a grid of sample sizes n ∈ {nmin, ..., nmax}. For each n in the grid, compute the statistical power
using steps 2-4 and for each n in the grid calculate the power.
1. Draw Y new,i ∼ p(Y new | η), i = 1, ..., I1 where the input parameters η are given by the stage-1
treatment response probabilities and end-of-study response probabilities.
2. Draw φ
(m),i
j ∼ p(φ | Y new,i) for all i = 1, ..., I1 and j = 1, ..., J1, m = 1, ...,M .
3. Compute U (l)
(
φ
(1),i
j , ..., φ
(M),i
j
)
, l = 1, ..., L.
4. Iterate steps 2-4, M (e.g., M = 500) times and repeat until n is sufficiently large so that
1
I1
I1∑
i=1
1
J1
J∑
j=1
I
 ⋂
l:∆l≥∆
{
U (l)(φ
(1),i
j , ..., φ
(M),i
j ) < 0
} ≥ 1− γ.
5 Simulation studies
5.1 SMART design 1 simulation study
See Figure 1 for a flow chart of the simulation design 1 SMART. Design 1 includes 6 embedded treatment
sequences and 4 embedded DTRs. People who respond to their stage-1 treatment continue on the same
treatment, whereas non-responders are re-randomized to one of two rescue treatments. The following is the
simulation scheme:
1. Stage-1 treatment assignment: A1 ∈ {−1, 1} with probability = 0.5.
2. Stage-1 treatment response indicator: S ∼ Bern(λA1), A1 ∈ {−1,+1}.
3. Stage-2 treatment for non-responders: A2 ∈ {−1, 1} with probability = 0.5.
4. Final binary outcome: YZi ∼ Bern(piZi), i = 1, ..., n.
5.2 General SMART simulation study
See Figure 2 for a flow chart of the simulation general SMART. The general SMART has 8 embedded
treatment sequences and 8 embedded DTRs. The following is the simulation scheme:
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n = 100 n = 400
Bayesian MSM Bayesian MSM
Design 1 Bias SD Bias SD Bias SD Bias SD
θ1 0.0024 0.0725 0.0025 0.0819 0.0028 0.0397 0.0031 0.0409
θ2 0.0043 0.0722 0.0051 0.0816 0.0010 0.0393 0.0010 0.0404
θ3 0.0204 0.0730 0.0061 0.0822 0.0045 0.0397 0.0026 0.0409
θ4 0.0080 0.0768 0.0028 0.0874 0.0024 0.0441 0.0006 0.0461
General Bias SD Bias SD Bias SD Bias SD
θ1 0.0172 0.0833 0.0025 0.1002 0.0027 0.0475 0.0054 0.0513
θ2 0.0038 0.0845 0.0025 0.1017 0.0021 0.0494 0.0038 0.0533
θ3 0.0432 0.0703 0.0059 0.0768 0.0114 0.0398 0.0041 0.0389
θ4 0.0297 0.0769 0.0072 0.0859 0.0107 0.0432 0.0022 0.0440
θ5 0.0194 0.0812 0.0011 0.0976 0.0067 0.0440 0.0019 0.0471
θ6 0.0239 0.0802 0.0001 0.0942 0.0072 0.0428 0.0005 0.0454
θ7 0.0183 0.0781 0.0004 0.0951 0.0052 0.0442 0.0007 0.0481
θ8 0.0228 0.0772 0.0015 0.0915 0.0057 0.0435 0.0007 0.0455
Table 3: Simulation SMART designs with 4 embedded DTRs and one with 8, respectively. Embedded DTR
performance estimates are given using our Bayesian approach compared with “weighted and replicated”
logistic regression with a marginal structural model m(β,A) = β0 + β1A1 + β2A
R
2 + β3A
NR
2 + β4A1A
R
2 +
β5A1A
NR
2 (Kidwell et al. , 2018; Nahum-Shani et al. , 2012; Almirall et al. , 2014).
1. Stage-1 treatment assignment: A1 ∈ {−1, 1} with probability = 0.5.
2. Stage-1 treatment response indicator: S ∼ Bern(λA1), A1 ∈ {−1,+1}.
3. Stage-2 treatment for responders to stage-1 treatment (S = 1): AR2 ∈ {−1, 1} with probability = 0.5.
4. Stage-2 treatment for non-responders to stage-1 treatment (S = 0): ANR2 ∈ {−1, 1} with probability =
0.5.
5. The final binary outcome is: Yi ∼ Bern(piZi), i = 1, ..., n.
One could incorporate covariates in either simulation scheme, but this would impose modeling assump-
tions which may lead to misspecification if, for example, probit or logistic regression is employed. Further-
more, including covariates would complicate the power analysis procedure as well as the interpretation of
MCB. Hence, we directly simulate the variables based off the probabilities of response.
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Figure 3: Power vs. sample size plots for SMART simulations with 4 and 8 embedded DTRs, respectively.
The predicted power is close to the empirical power. The black horizontal line corresponds to 80% power.
5.3 Simulation: results
Table 3 shows the bias and SD for our Bayesian estimation approach and for a frequentist approach weighted
and replicated logistic regression with the marginal structural model (MSM)
m(β,A) = β0 + β1A1 + β2A
R
2 + β3A
NR
2 + β4A1A
R
2 + β5A1A
NR
2 .
We see that the bias is similar between the Bayesian procedure and MSM. The Bayesian procedure has
slightly smaller SE.
To compute the empirical power, we simulated 1000 datasets over a grid of sample sizes, 150, 200, ..., 500.
We used 1000 Monte Carlo draws for each of the 1000 datasets to obtain 1000 upper credible interval limits
for each embedded DTR, e.g., U
(l)
i , l = 1, ..., L and i = 1, ..., 1000 for each embedded DTR i and each sample
size. We then computed the empirical power as
Power ≈ 1
1000
1000∑
i=1
I
 ⋂
l:∆l≥∆min
{
U
(l)
i < 0
}
where ∆l = log
(
OddsL
Oddsl
)
where ∆min was set to ∆min = 0.61 for Design 1 with ∆ = (0.59, 1.30, 0.67, 0.00)
>.
Then, EDTR2 and EDTR3 should be excluded from the set of best.
We chose ∆min = 0.9 with ∆ = (0.93, 1.93, 0.00, 1.14, 2.66, 1.94, 0.84, 0.17)
>. Then, EDTR2,EDTR4,
EDTR5,EDTR6, and EDTR8 should be excluded from the set of best. The power plots (Figure 3) demon-
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Figure 4: Real ENGAGE SMART MCB. Upper one-sided credible intervals for the difference between each
embedded DTR (EDTR) and the best embedded DTR. Intervals covering 0 indicate that the correspond-
ing embedded DTR is not statistically significantly inferior to the best embedded DTR. Being below zero
indicates inferiority compared with the best.
strate the accuracy of the predicted power estimating the required sample size.
6 Constructing a set of best embedded DTRs for the ENGAGE
SMART
In this section, we apply our method to the The Adaptive Treatment for Alcohol and Cocaine Dependence
(ENGAGE) SMART trial to construct a set of optimal embedded DTRs for a binary outcome. We di-
chotomize the log of the sum of the total number of days drinking plus the total number of days using
cocaine plus a small constant 0.5 and consider a positive response to be having the outcome less than
the 25th percentile. We see that the optimal embedded DTRs are embedded DTRs 1 and 2. The one
with the lowest point estimate is embedded DTR 2. This suggests that MI-IOP is superior to patients’
choosing their own care. Furthermore, although not statistically significant different, stage-2 NFC has
a greater point estimate compared to MI-PC. The probability of response in each embedded DTR was
(EDTR1,EDTR2,EDTR3,EDTR4) = (0.38, 0.41, 0.19, 0.22).
The actual power is approximately 57% for a sample size of 148, the actual sample size in the SMART. To
achieve a power of 80% would require a sample size of approximately 250 subjects and for 90%, approximately
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Figure 5: Power for ENGAGE SMART to exclude all embedded DTRs except for the third (MI-PC stage 1,
MI-PC stage 2). The actual power is 57%.
350 subjects. The proposed MCB analysis demonstrates that the embedded DTR for which there is no further
care are not statistically distinguishable from the embedded DTR for which patient choice is offered in stage
2. Therefore, clinicians may choose from the set of best either embedded DTR considering other factors such
as costs, treatment burden and patients preference.
7 Input parameters for sample size calculation
The input parameters are the final response rates for each embedded treatment sequence θk for k = 1, ...,K,
and the stage-1 treatment response probabilities λA1 for A1 ∈ {−1,+1}. For the treatment sequences in
which patients responded to the first stage treatment (probability λA1) when continuing initial treatment,
the response rate from non-SMART studies may be used. For sequences involving two sequential treatments,
the response rates of the second stage treatment will yield a conservative estimate of the power, so in the
absence of data on a particular sequence of treatments, one may choose the response rate of the second
stage treatment obtained from existing literature. Furthermore, one may equate different branch response
probabilities essentially making the assumption of no interaction between stage-1 treatment and the response
rate for a particular stage-2 treatment. This may be reasonable for a SMART in which both branches have
the same treatment options in stage 2. As an alternative, one may conduct a pilot SMART to estimate the
response rates (Artman et al. , 2018; Rose et al. , 2019).
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8 Discussion
An important goal of SMARTs is the determination of the best embedded DTRs. Subjects with substance use
disorders are heterogeneous in their response to outcome. The optimal embedded DTRs for the ENGAGE
study were those which consisted of the intensive out patient programs. Previous work has focused on
inference for simple comparisons such as those between two embedded DTRs. Furthermore, methods which
are applicable to more complex comparisons such as determination of the optimal embedded DTR while
taking into account uncertainty has focused on continuous outcomes in the frequentist setting. We made
two main contributions. First, we extended existing methodologies from continuous to binary outcomes and
from the frequentist to the Bayesian setting. In particular, we applied the algorithm in Mandel & Betensky
(2008) to MCB to construct a set of optimal embedded DTRs. Secondly, we provide a means for sample
size calculations without the need for knowledge of the covariance matrix of log-odds ratios and without
normality assumptions.
We proved the validity of our method and demonstrated its application on real data, the ENGAGE
SMART. Recently, there has been work to develop sample size formula based off Q-learning for a continuous
outcome in Rose et al. (2019). It would be of interest to extend the proposed Bayesian MCB framework
to Q-learning with binary outcomes. Furthermore, it would be valuable to extend MCB to constructing a
set of best for longitudinal outcomes or zero-inflated outcomes. It would be straightforward to extend the
Bayesian approach to encompass continuous outcomes.
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A Proofs
A.1 Robin’s G-Computation formula
Pr(Y (l) = 1) = Pr(Y = 1 | A1,EDTR(l))
= Pr(Y = 1 | A1, S = 1,EDTR(l)) Pr(S = 1 | A1,EDTR(l))
+ Pr(Y = 1 | A1, S = 0,EDTR(l)) Pr(S = 0 | A1,EDTR(l))
= Pr(Y = 1 | A1, S = 1) Pr(S = 1 | A1) + Pr(Y = 1 | A1, S = 0, ANR2 ) Pr(S = 0 | A1)
A.2 Proof of credible interval coverage
We wish to construct simultaneous 100(1 − α)% one-sided upper credible intervals for ζ(l), l = 1, ..., L.
Denote the upper limit for the lth embedded DTR by U (l). Then, U (l) satisfies
Pr
(
L⋂
l=1
{ζ(l) ≤ U (l)}
)
= 1− α.
This is equivalent to
M−1
M∑
m=1
I
(
L⋂
l=1
{ζ(l)m ≤ U (l)}
)
= M−1
M∑
m=1
I
(
L⋂
l=1
{ζ(l)(r(m,l),l) ≤ U (l)}
)
M−1
M∑
m=1
I
(
L⋂
l=1
{ζ(l)(r(m,l),l) ≤ U (l)}
)
→ 1− α as M →∞.
Let U (l) = ζ
(l)
(r1−αl)
where r1−α is the 1− α quantile of r(1), ..., r(M) where r(m) = maxl r(m, l). Then,
M−1
M∑
m=1
I
(
L⋂
l=1
{ζ(l)(r(m,l),l) ≤ U (l)}
)
= M−1
M∑
m=1
I
(
L⋂
l=1
{ζ(l)(r(m,l),l) ≤ ζ(l)(r1−αl)}
)
= M−1
M∑
m=1
I
(
L⋂
l=1
{r(m, l) ≤ r1−α}
)
= M−1
M∑
m=1
I
(
max
l
r(m, l) ≤ r1−α}
)
= M−1
M∑
m=1
I (r(m) ≤ r1−α})→ 1− α.
QED.
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